ADVANZ PHARMA - M&A Summary, Ownership, and Business Overview

Life ScienceCompany

ADVANZ PHARMA M&A Summary

ADVANZ PHARMA has acquired 6 companies of its own, including 2 in the last 5 years. A total of 1 acquisition came from private equity firms. It has also divested 1 asset.

ADVANZ PHARMA’s largest acquisition to date was in 2015, when it acquired Amdipharm Mercury - AMCo. for $3.5B. It’s largest disclosed sale occurred in 2015, when it sold Concordia Pharmaceuticals - Frotaz Zinacef ad Zantac Injection to Teligent for $10M. ADVANZ PHARMA has acquired in 3 different US states, and 4 countries. The Company’s most targeted sectors include life science (67%) and healthcare services (17%).

ADVANZ PHARMA Ownership

Who owns ADVANZ PHARMA?

ADVANZ PHARMA is owned by Nordic Capital. It was acquired on January 27, 2021.

Is ADVANZ PHARMA PE-backed?

Yes. ADVANZ PHARMA is owned by private equity investor Nordic Capital.

ADVANZ PHARMA Business Overview

Where is ADVANZ PHARMA headquartered?

ADVANZ PHARMA is headquartered in London, United Kingdom.

What is ADVANZ PHARMA’s revenue?

ADVANZ PHARMA disclosed revenue of 508M USD for 2019 and 537M USD for 2018.

How many employees does ADVANZ PHARMA have?

ADVANZ PHARMA has 675 employees.

What sector is ADVANZ PHARMA in?

ADVANZ PHARMA is a life science company.

When was ADVANZ PHARMA founded?

ADVANZ PHARMA was founded in 1963.

M&A Summary

  • M&A Total Activity7
    • M&A Buy Activity6
    • M&A Sell Activity1
  • Total Sectors Invested 3
  • Total Countries Invested 4
  • M&A Buy/Sell Connections 4
  • M&A Advisors 8

ADVANZ PHARMA

ADVANZ PHARMA Corp.

Dashwood House, 2nd Floor, 69 Old Broad Street,
London, EC2M 1QS
United Kingdom,
+44 2085 889 100
www.advanzpharma.com

ADVANZ PHARMA is a specialty pharmaceutical company with a strategic focus on complex medicines with direct sales access in Europe and a global distribution network. ADVANZ PHARMA was founded in 1963 and is based in London, United Kingdom.


M&A Summary

Buy vs Sell

Year ≤ '19 '20 '21 '22 '23 '24 T
Buy (0.2/yr) # 5 1 - - - - 6
vol $4.9B $76M $5.0B
Sell (0.0/yr) # 1 - - - - - 1
vol $10M $10M
  7

Most Recent M&A

Company Date Value Type
Correvio Pharma Corp. 2020-03-16 76M USD Add-on Acquisition
Vancouver, British Columbia · www.correvio.com
Eisai, Inc. - Two Medicines (Salagen & Panretin) 2019-04-01 33M USD Divestiture
Woodcliff Lake, New Jersey
Concordia Pharmaceuticals, Inc. - Frotaz Zinacef ad Zantac Injection 2015-10-05 10M USD Divestiture
Oakville, Ontario
Amdipharm Mercury Co., Ltd. - AMCo. 2015-09-08 3.5B USD Add-on Acquisition
Croydon, United Kingdom · www.amcolimited.com
Covis Pharma Sàrl 2015-03-15 1.2B USD Divestiture
Luxembourg, Switzerland · www.covispharma.ch
Donnatal 2014-03-20 200M USD Divestiture
, United States
Pinnacle Biologics, Inc. 2013-12-24 - Add-on Acquisition
Bannockburn, Illinois
View All >>

Business Unit M&A

Company Acquired Add-On/Sale Date #
Covis Pharma Sàrl 2015-03-15 AstraZeneca Plc - Alvesco, Omnaris and Zetonna Business 2018-11-06 2
Luxembourg, Switzerland · www.covispharma.ch London, United Kingdom

M&A by Sector

Sector Buy # Value Sell # Value
Life Science 4 (67%) 3.6B (72%) 1 (100%) 10M (100%)
Healthcare Services 1 (17%) 1.2B (24%) - -
Medical Products 1 (17%) 200M (4%) - -
Total 6 $5.0B 1 $10M

By Geo

State/Country Buy Value Sell Value
United States 3 233M - -
  New Jersey 1 33M - -
  Illinois 1 - - -
Canada 1 76M 1 10M
  British Columbia 1 76M - -
  Ontario - - 1 10M
Switzerland 1 1.2B - -
United Kingdom 1 3.5B - -
Domestic 1 (17%) 3.5B (70%) - -
Cross-border 5 (83%) 1.5B (30%) 1 (100%) 10M (100%)
Total 6 $5.0B 1 $10M

Top M&A Advisors

Financial Deals
Torreya Partners LLC
1
PJT Partners, Inc.
1
Goldman Sachs
1
Legal Deals
Sullivan & Cromwell
2
Fasken Martineau DuMoulin
2
White & Case
1

Deal Values

buy # Total
> $1B 2 $4.7B
$100M to $1B 1 $200M
< $100M 2 $109M
TOTAL $5.0B
Largest Amdipharm Mercury Co., Ltd. - AMCo.
$3.5B (2015-09-08)
sell # Total
< $100M 1 $10M
TOTAL $10M
Largest Concordia Pharmaceuticals, Inc. - Frotaz Zinacef ad Zantac Injection
$10M (2015-10-05)

M&A Connections

Deals
Acquired from
Investor(s)
17%
1 (17%)
Strategic(s)
33%
2 (33%)
Divested to
Strategic(s)
100%
1 (100%)

 Subscribe to unlock this and 208,055
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 201K M&A Transactions
  • 203K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 81K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.

Related Lists for ADVANZ PHARMA

Life Science Companies , United Kingdom Companies